Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 20 of 20 results for alemtuzumab

  1. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

    NICE guideline
    Published
    22 June 2022
    View recommendations

    Sections for NG220

  2. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA193

  3. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  4. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  5. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued Reference number: GID-TA10527

    Technology appraisal guidance
    Discontinued